Cephalosporin esters

Details Cephalosporin esters Cephalosporin esters

C - Chemistry, Metallurgy

07

D

260/106.1

C07D 501/36 (2006.01) C07D 257/04 (2006.01) C07D 333/24 (2006.01)

Patent

CA 1135255

Abstract of the Disclosure This specification discloses novel compounds and intermediates and processes leading thereto. The novel com- pounds have the structure: Image wherein. R1 is acyl or hydrogen and n is an integer of 1 to 9 inclusive, and R3 is H or methoxy, or an ester or a nontoxic pharmaceutically acceptable salt thereof. Said ester of the compounds of the formula I include those having the group of the formula Image . The specification also provides salts of these acids. The stereochemistry of the bicyclic nucleus is that found in Cephalosporin C. In the treatment of bacterial infections in man, the novel compounds disclosed herein are administered parenterally or orally in an amount of from about 5 to 200 mg./kg./day and preferably about 5 to 20 mg./kg./day in dividcd dosage, e.g. three to four times a day. They are administered in dosage units containing, for example, 125, 250 or 500 mg. of active ingredient with suitable physiologically acceptable carriers or excepients. The dosage units are in the form ofr liquid preparations such as solutions or suspensions.

234276

Affiliated with

Also associated with

Rating

Cephalosporin esters does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cephalosporin esters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cephalosporin esters will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-322509